Recursion Pharmaceuticals vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Public AI drug discovery platform (NASDAQ: RXRX). 5 clinical programs. Merged with Exscientia ($688M). 2025 rev $74.7M. $755M cash. Founded 2013, Salt Lake City.
About
Recursion Pharmaceuticals (NASDAQ: RXRX) is a computational biology company industrializing drug discovery with AI, founded in 2013 in Salt Lake City, Utah. Built Recursion OS, a vertically integrated platform unifying biology, chemistry, and clinical development. Completed $688M all-stock Exscientia merger (November 2024). Market cap ~$1.62B.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Recursion Pharmaceuticals vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.